Fate Therapeutics (FATE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 13,631 | 63,533 | 96,300 | 55,846 | 31,434 |
| Gross Profit | 13,631 | 63,533 | 96,300 | 55,846 | 31,434 |
| Operating Expenses | 223,907 | 254,044 | 404,686 | 272,840 | 159,519 |
| Operating Income | -210,276 | -190,511 | -308,386 | -216,994 | -128,085 |
| Other Income | 24,014 | 29,583 | 26,665 | 4,843 | -45,302 |
| Pre-tax Income | -186,262 | -160,928 | -281,721 | -212,151 | -173,387 |
| Net Income Continuous | -186,262 | -160,928 | -281,721 | -212,151 | -173,387 |
| Net Income | $-186,262 | $-160,928 | $-281,721 | $-212,151 | $-173,387 |
| EPS Basic Total Ops | -1.64 | -1.64 | -2.91 | -2.24 | -2.10 |
| EPS Basic Continuous Ops | -1.64 | -1.64 | -2.91 | -2.24 | -2.10 |
| EPS Diluted Total Ops | -1.64 | -1.64 | -2.91 | -2.24 | -2.10 |
| EPS Diluted Continuous Ops | -1.64 | -1.64 | -2.91 | -2.24 | -2.10 |
| EPS Diluted Before Non-Recurring Items | -1.51 | -1.64 | -2.91 | -2.36 | -1.52 |
| EBITDA(a) | $-200,394 | $-176,431 | $-292,208 | $-202,082 | $-120,212 |